DPHARMA | DUOPHARMA BIOTECH BHD

6
3.09 (-2.52%)

T-O: 3.18 (08:59:00)
Last updated: 17:00

Fundamental   5.6  
Technical   4.2  
Total Score   9.8  

 Insti+ 
DPHARMA | DUOPHARMA BIOTECH BHD


Fundamental

iSaham Fundamental Trend

FCON: 0.65 | Sharpe Ratio: 0.55 | LTS: 7.81


Quarter Reports

Trailing Dividend

Financial Ratios

EPS 9.48 sen
Trailing PE (Sector Median: 24.6) 34.8
PEG 0.77
Altman Z 1.4
Beaver 0.0
Current Ratio 2.57
Debt-Equity (DE) Ratio 0.73
FCF Yield -1.21 %
Revenue QoQ 4.88 %
Revenue YoY -1.22 %
Profit QoQ 29.89 %
Profit YoY 15.26 %
All-Time Profit Margin (Sector Median: 1.1) 16.5 %
ROE (ROIC: 6.99) 9.81 %
Dividend Per Share (DPS) 6.5 sen
Dividend Yield (DY) 2.1 %

Fair Value

Weighted Average Fair Value: 2.75

Discounted Cash Flow (DCF) 5% Growth 0.91
Discounted Cash Flow (DCF) 10% Growth 1.2
Relative Valuation 2.18
Average Analysts FV based on 3 rating(s), +7.8% 3.33
Graham Formula 0.71
Graham Number 1.39
Net Tangible Asset (NTA) 0.9
Consistent QR FV N/APremium Access Only

Advanced Calculators

Calculate the fair value of the stock based on expected growth / risk, contract / award value, forecasted profit or forecasted revenue.

Forward PE FV Calculator
Latest Profit 16.39
Expected Profit (Next QR) [M]
Expected Profit (After QR above) [M]
Expected Profit (After QR above) [M]
Estimated Fair Value
Growth/Risk Fair Value Calculator
Expected growth (%)
Estimated downside / risk (%)
Estimated New DCF Fair Value
Contract/Award Contribution Calculator
Contract/Award Value (in Million)
Estimated Contribution to Stock Price
Estimated New DCF Fair Value
Profit-Based Calculator
Expected Profit (M)
for Year
Estimated New DCF Fair Value
Revenue-Based Calculator
Expected Revenue (M)
for Year
Estimated New DCF Fair Value
Market Pricing
Expected Profit (M) 461.63
Expected Revenue (M) 4254.63
Expected Growth (%) 31.0

Directors Share Purchases (Beta)


No transaction in the last 2 months.

Technical

Summary

Market Cap: 2182 M.

Number of Shares: 706 M.

Adjusted Float: 40.43%.

Stock highly correlated with

PHARMA (97%)

MENANG (95%)

RGTBHD (95%)

SCOMNET (95%)

Manipulation Indicator: Very hard to manipulate.

Duopharma Biotech Group was incorporated in 2000 and is today one of Malaysia’s leading pharmaceutical companies listed on the Main Market of Bursa Malaysia Berhad. Duopharma Biotech has core competencies in the pharmaceutical industry inclusive of Manufacturing, Research & Development and Commercialisation & Marketing of over 300 generic drugs such as Omesec and Prelica as well as Consumer Healthcare (“CHC”) products. The Company has also diversified into the biosimilars space with technology and commercialisation collaborations with credible and strong international partners. Headquartered in Kuala Lumpur, Malaysia, Duopharma Biotech owns and operates three manufacturing plants in Klang, Bangi and Glenmarie, Selangor. Duopharma Biotech also has subsidiary companies in the Philippines and Singapore. A subsidiary of Duopharma Biotech Berhad has a representative office in Jakarta, Indonesia.

Sectors: Consumer Products, Healthcare, Pharmaceuticals, Technology, Budget 2021, Post MCO, Vaccine

Code: 7148

Website: http://duopharmabiotech.com/

Related Links: Bursa | Annual Report | Announcement

Top Shareholdings

Updated on 25-Mar-2020

Shareholder Value (M)
Permodalan Nasional Berhad 981.14
Employees Provident Fund Board 176.59
Amanah Saham Bumiputera 92.7
Billion Victory Sdn Bhd 52.78
Public Islamic Treasures Growth Fund 22.28
Norges Bank 21.0
Manulife Investment Shariah Progressfund 20.85
Kumpulan Wang Persaraan (Diperbadankan) 15.78
Principal Dali Opportunities Fund 14.28
Eastspring Investmentssmall-Cap Fund 12.96
Manulife Investment Progress Fund 12.96
Lembaga Tabung Haji 12.43
Affin Hwang Aiiman Asia (Ex Japan) Growth Fund 10.4
Amanah Saham Malaysia 3 9.62
Tokio Marine Life Insurance Malaysia Bhd 8.75
Principal Islamic Small Cap Opportunities Fund 8.44
Affin Hwang Growth Fund 7.52
Ooi Keng Tan 6.82
CIMB-Principal Small Cap Fund 6.62
Petroliam Nasional Berhad 6.51
Gibraltar BSN Aggressive Fund 6.14
Affin Hwang Principled Growth Fund 6.11
Medical Fund 5.73
Credit Suisse 5.72
Amtotal Return 5.45
Hong Leong Assurance Berhad 5.32
Areca Equitytrust Fund 5.09